2nd Annual Global Summit on Hematologic Malignancies-Asia
April 18 - 20, 2019
Oncology Meeting Innovations’ Annual Summit on Hematologic Malignancies fosters discussion and debate on the evolution of treatment of hematologic malignancies and features a focused approach towards individual patient populations through case-based discussions. In response to changes in the clinical landscape of chronic lymphocytic leukemia, multiple myeloma, lymphomas and acute leukemias, the summit assembles translational researchers, clinical researchers and key community oncologists to address the challenges of this rapidly evolving area of oncology.
- How new agents targeting BTK, PI3K delta and BCL-2, as well as next-generation CD20 monoclonal antibodies are changing the landscape and treatment paradigms for CLL
- Treatment advances in multiple myeloma including recent data on drugs targeting CD38, SLAMF7, and HDAC in addition to novel approaches to proteasome inhibition
- Identifying and analyzing advances in the understanding of the molecular biology and microenvironment in treating lymphoma and acute leukemia
- Novel strategies such as chimeric antigen receptor T-cell therapy, checkpoint inhibition and next-generation antibody therapy in treating hematologic malignancies
Kensei Tobinai, MD, PhD
Visiting Scientist National Cancer Center Hospital Tokyo, Japan
John Pagel, MD, PhD
Chief of Hematologic Malignancies Swedish Cancer Institute Seattle, WA
Hilton Tokyo Bay Hotel
Located on the eastern shore of Tokyo Bay, the hotel combines ocean views with ease of access to central Tokyo, just a 30-minute drive. Situated within Tokyo Disney Resort®, the hotel is a stroll away from the theme parks. The hotel is also a short 20 minutes from Tokyo Station and Marunouchi financial district.